Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study)

Figures & data

Figure 1 EDSS score distribution at baseline.

Abbreviation: EDSS, expanded disability status scale.

Table 1 Patient demographics

	Study center						Total
	Sønderberg	Vejle	Roskilde	Glostrup	Hillerød	Sandvika
Patients, n	10	1	10	26	8	5	60
Female, n (%)	8 (80)	1 (100)	9 (90)	23 (88)	6 (75)	3 (60)	50 (83)
Age in years, mean (SD)	42.0 (5.0)	47.4 (NA)	45.7 (6.0)	44.6 (9.1)	41.8 (8.3)	40.3 (10.0)	43.7 (7.9)
Employment status, n (%)
Full time	3 (30)	0 (0)	0 (0)	7 (27)	1 (13)	3 (60)	14 (23)
Part time	5 (50)	1 (100)	4 (40)	10 (38)	4 (50)	1 (20)	25 (42)
Unemployed	2 (20)	0 (0)	6 (60)	9 (35)	3 (38)	1 (20)	21 (35)
Education status, n (%)
Elementary	3 (30)	0 (0)	4 (40)	2 (8)	0 (0)	0 (0)	9 (15)
Intermediate	6 (60)	0 (0)	6 (60)	18 (69)	7 (87.5)	3 (60)	40 (67)
Higher	1 (10)	1 (100)	0 (0)	6 (23)	1 (12.5)	2 (40)	11 (18)
Marital status, n (%)
Single/divorced	5 (50)	1 (100)	1 (10)	5 (19)	1 (13)	1 (20)	14 (23)
Married/living with partner	5 (50)	0 (0)	9 (90)	21 (81)	7 (87)	4 (80)	46 (77)

Table 2 MS history

	Mean value (±SD), years
Age at the time of first attack	34.5 (8.1)
Time since first attack	9.1 (5.8)
Age at the time of MS diagnosis	37.0 (7.6)
Time since MS diagnosis	6.7 (4.5)
Time since last clinical relapse	4.0 (3.3)

Abbreviation: MS, multiple sclerosis.

Figure 2 Distribution of patients for each 5% tier of adherence.

Table 3 Adherence to RebiSmart^®

Adherence	Patients, N (%; exact Clopper–Pearson 95% CI)
≥75%	51 (94; 85–99)
≥80%	50 (93; 82–98)
≥85%	49 (91; 80–97)
≥90%	47 (87; 75–95)
≥95%	41 (76; 62–87)
≥100%	34 (63; 49–76)